Naldebain for Pain Management After Knee Arthroplasty
Status:
Recruiting
Trial end date:
2024-10-31
Target enrollment:
Participant gender:
Summary
Naldebain, a long-acting analgesic injection, obtained a license from the Taiwan Food and
Drug Administration (TFDA) of the Ministry of Health and Welfare on March 6, 2017 to approve
a sustained-release long-acting analgesic on the market in Taiwan. This study hopes to use a
rigorous double-blind randomized controlled experiment to understand whether the new
sustained-release analgesic Naldebain can achieve effective pain relief for patients
undergoing knee replacement surgery, and to evaluate the patient's functional recovery status
.
Phase:
Phase 4
Details
Lead Sponsor:
Kaohsiung Medical University Chung-Ho Memorial Hospital